SIGA (SIGA) 10-K 4 Mar 21 2020 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2020	Feb. 16, 2021	Jun. 30, 2020
Document Information [Line Items]
Entity Central Index Key	0001010086
Entity Registrant Name	Siga Technologies INC
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2020
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2020
Document Transition Report	false
Entity File Number	0-23047
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	13-3864870
Entity Address, Address Line One	31 East 62nd Street
Entity Address, Postal Zip Code	10065
Entity Address, City or Town	New York
Entity Address, State or Province	NY
City Area Code	212
Local Phone Number	672-9100
Title of 12(b) Security	common stock, $.0001 par value
Trading Symbol	SIGA
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 306,491,182
Entity Common Stock, Shares Outstanding		76,748,446

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Current assets
Cash and cash equivalents	$ 117,890,240	$ 65,249,072
Restricted cash and cash equivalents, short-term	0	95,737,862
Accounts receivable	3,340,263	4,167,996
Inventory	20,265,519	9,652,855
Prepaid expenses and other current assets	2,112,069	5,234,000
Total current assets	143,608,091	180,041,785
Property, plant and equipment, net	2,103,990	2,618,303
Deferred tax asset, net	2,544,053	14,151,002
Goodwill	898,334	898,334
Other assets	676,923	856,766
Total assets	149,831,391	198,566,190
Current liabilities
Accounts payable	1,278,217	3,054,032
Accrued expenses and other current liabilities	9,205,293	8,636,911
Term debt, current	0	80,044,866
Total current liabilities	10,483,510	91,735,809
Warrant liability	6,639,211	6,116,882
Other liabilities	2,915,401	2,929,743
Total liabilities	20,038,122	100,782,434
Commitments and contingencies (Note 14)
Stockholders' equity
Common stock ($.0001 par value, 600,000,000 shares authorized, 77,195,704 and 81,269,868 issued and outstanding at December 31, 2020 and December 31, 2019, respectively)	7,720	8,127
Additional paid-in capital	224,978,430	220,808,037
Accumulated deficit	(95,192,881)	(123,032,408)
Total stockholders' equity	129,793,269	97,783,756
Total liabilities and stockholders' equity	$ 149,831,391	$ 198,566,190

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2020	Dec. 31, 2019
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	600,000,000	600,000,000
Common stock, shares issued (in shares)	77,195,704	81,269,868
Common stock, shares outstanding (in shares)	77,195,704	81,269,868

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Revenues
Total revenues	$ 124,959,304	$ 26,742,085	$ 477,053,782
Operating expenses
Cost of sales and supportive services	14,797,419	1,782,838	95,268,974
Selling, general and administrative	14,003,184	13,252,136	12,879,738
Research and development	10,938,930	13,303,149	13,016,183
Patent expenses	719,141	726,105	789,489
Total operating expenses	40,458,674	29,064,228	121,954,384
Operating income (loss)	84,500,630	(2,322,143)	355,099,398
(Loss) gain from change in fair value of warrant liability	(3,525,846)	5,091,256	(6,922,624)
Loss on extinguishment of Term Loan	(4,981,461)	0	0
Interest expense	(3,016,817)	(15,769,768)	(15,478,203)
Other income, net	532,085	2,822,232	78,940,985
Income (loss) before income taxes	73,508,591	(10,178,423)	411,639,556
(Provision) benefit for income taxes	(17,166,581)	2,937,276	10,168,272
Net and comprehensive income (loss)	$ 56,342,010	$ (7,241,147)	$ 421,807,828
Basic earnings (loss) per share (in dollars per share)	$ 0.71	$ (0.09)	$ 5.28
Diluted earnings (loss) per share (in dollars per share)	$ 0.71	$ (0.15)	$ 5.18
Weighted average shares outstanding: basic (in shares)	79,259,000	81,031,254	79,923,295
Weighted average shares outstanding: diluted (in shares)	79,437,306	82,175,023	82,708,472
Product Sales and Supportive Services [Member]
Revenues
Total revenues	$ 115,471,071	$ 11,190,064	$ 468,918,468
Research and Development [Member]
Revenues
Total revenues	$ 9,488,233	$ 15,552,021	$ 8,135,314

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity (Deficiency) - USD ($)	Cumulative Effect, Period of Adoption, Adjustment [Member]Common Stock [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]Additional Paid-in Capital [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]Retained Earnings [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]AOCI Attributable to Parent [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance (in shares) at Dec. 31, 2017						79,039,000
Balance at Dec. 31, 2017			$ (223,313)		$ (223,313)	$ 7,904	$ 214,229,581	$ (537,375,776)	$ 0	$ (323,138,291)
Net income (loss)								421,807,828		421,807,828
Issuance of common stock upon exercise of stock options (in shares)						426,366
Issuance of common stock upon exercise of stock options						$ 42	261,837			261,879
Issuance of common stock upon vesting of RSUs and exercise of stock-settled appreciation rights (in shares)						1,184,283
Issuance of common stock upon vesting of RSUs and exercise of stock-settled appreciation rights						$ 118				0
Issuance of common stock upon vesting of RSUs and exercise of stock-settled appreciation rights							(118)
Issuance of common stock upon exercise of warrants (in shares)						760,626
Issuance of common stock upon exercise of warrants						$ 77	6,007,770			6,007,847
Payment of common stock tendered for employee stock-based compensation tax obligations (in shares)						(646,925)
Payment of common stock tendered for employee stock-based compensation tax obligations						$ (65)	(4,074,375)			(4,074,440)
Stock-based compensation							2,273,177			2,273,177
Balance (in shares) at Dec. 31, 2018						80,763,350
Balance at Dec. 31, 2018						$ 8,076	218,697,872	(115,791,261)	0	102,914,687
Net income (loss)								(7,241,147)		(7,241,147)
Issuance of common stock upon exercise of stock options (in shares)						9,769
Issuance of common stock upon exercise of stock options						$ 1				0
Issuance of common stock upon vesting of RSUs and exercise of stock-settled appreciation rights (in shares)						515,888
Issuance of common stock upon vesting of RSUs and exercise of stock-settled appreciation rights						$ 52				0
Issuance of common stock upon vesting of RSUs and exercise of stock-settled appreciation rights							(52)
Issuance of common stock upon exercise of warrants (in shares)						159,782
Issuance of common stock upon exercise of warrants						$ 16	1,172,785			1,172,801
Payment of common stock tendered for employee stock-based compensation tax obligations (in shares)						(232,253)
Payment of common stock tendered for employee stock-based compensation tax obligations						$ (23)	(1,176,556)			(1,176,579)
Stock-based compensation							2,113,994			2,113,994
Issuance of common stock upon exercise of stock options							(1)
Issuance of common stock to employees (in shares)						53,332
Issuance of common stock to employees						$ 5	(5)			0
Balance (in shares) at Dec. 31, 2019						81,269,868
Balance at Dec. 31, 2019						$ 8,127	220,808,037	(123,032,408)	0	97,783,756
Net income (loss)								56,342,010		56,342,010
Issuance of common stock upon exercise of stock options (in shares)						11,822
Issuance of common stock upon exercise of stock options						$ 1				0
Issuance of common stock upon exercise of warrants (in shares)						393,646
Issuance of common stock upon exercise of warrants						$ 40	3,003,477			3,003,517
Payment of common stock tendered for employee stock-based compensation tax obligations (in shares)						(29,035)
Payment of common stock tendered for employee stock-based compensation tax obligations						$ (3)	(184,013)			(184,016)
Stock-based compensation							1,350,948			$ 1,350,948
Issuance of common stock upon exercise of stock options							(1)
Repurchase of common stock (in shares)						(4,628,473)				(4,600,000)
Repurchase of common stock						$ (463)		(28,502,483)		$ (28,502,946)
Issuance of common stock upon vesting of RSUs (in shares)						177,876
Issuance of common stock upon vesting of RSUs						$ 18	(18)			0
Balance (in shares) at Dec. 31, 2020						77,195,704
Balance at Dec. 31, 2020						$ 7,720	$ 224,978,430	$ (95,192,881)	$ 0	$ 129,793,269

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Cash flows from operating activities:
Net income (loss)	$ 56,342,010	$ (7,241,147)	$ 421,807,828
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and other amortization	529,814	526,997	69,630
Loss (gain) on change in fair value of warrant liability	3,525,846	(5,091,256)	6,922,624
Stock-based compensation	1,350,948	2,113,994	2,273,177
Net realization of deferred revenue and costs due to FDA approval	0	0	(281,950,853)
Deferred income taxes provision (benefit)	11,606,949	(2,417,617)	(9,301,422)
Loss on extinguishment of Term Loan	4,981,461	0	0
Non-cash interest expense	887,132	4,497,271	4,497,273
Gain on sale of priority review voucher	0	0	(78,338,826)
Changes in assets and liabilities:
Accounts receivable	827,733	(2,208,863)	(49,723)
Inventory	(8,009,992)	(6,744,644)	39
Prepaid expenses and other assets	699,102	(714,272)	(2,579,329)
Accounts payable, accrued expenses and other liabilities	(2,204,381)	936,839	2,045,191
Deferred revenue	982,606	(1,861,605)	3,475,714
Net cash provided by (used in) operating activities	71,519,228	(18,204,303)	68,871,323
Cash flows from investing activities:
Capital expenditures	(15,501)	(29,094)	(102,264)
Net proceeds from sale of priority review voucher	0	0	78,338,826
Net cash (used in) provided by investing activities	(15,501)	(29,094)	78,236,562
Cash flows from financing activities:
Net proceeds from exercise of stock options	0	0	261,879
Payment of employee tax obligations for common stock tendered	(184,016)	(1,176,579)	(4,074,440)
Repurchase of common stock	(28,502,946)	0	0
Repayment of Term Loan	(85,913,459)	0	0
Net cash used in financing activities	(114,600,421)	(1,176,579)	(3,812,561)
Net (decrease) increase in cash and cash equivalents	(43,096,694)	(19,409,976)	143,295,324
Cash, cash equivalents and restricted cash at the beginning of period	160,986,934	180,396,910	37,101,586
Cash, cash equivalents and restricted cash at end of period	117,890,240	160,986,934	180,396,910
Supplemental disclosure of cash inflows information:
Conversion of warrant to common stock	3,003,517	1,172,801	6,007,847
Issuance of common stock upon cashless exercise	97,250	118,500	1,681,426
Cash income taxes paid (refund), net	$ 3,718,581	$ (1,276,129)	$ 251,961

Note 1 - Organization and Basis

Note 1 - Organization and Basis of Presentation	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Organization and Basis of Presentation Description of Business SIGA Technologies, Inc. (“SIGA” or the “Company”) is a commercial-stage pharmaceutical company. The Company's lead product, TPOXX® (“oral TPOXX®”) is a United States Food & Drug Administration-approved oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. On July 13, 2018,

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies Use of Estimates Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the periods reported. The most significant estimates include the variables used in the calculation of fair value of warrants granted or issued by the Company, reported amounts of revenue, and the valuation of deferred tax assets. Estimates and assumptions are reviewed periodically and the effects of revisions are reflected in the financial statements in the period they are determined to be necessary. Actual results could differ from these estimates. Basis of Presentation The consolidated financial statements and related disclosures are presented in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) and reflect the consolidated financial position, results of operations and cash flows for all periods presented. Cash Equivalents The Company considers all highly liquid investments with original maturities of three Restricted Cash and Cash Equivalents Under the terms of the Loan Agreement (as defined below), net cash proceeds from the Company's Priority Review Voucher ("PRV") sale on October 31, 2018 ( 4 8 second 2020 second 2020 The following table reconciles cash, cash equivalents and restricted cash per the consolidated statements of cash flows to the consolidated balance sheet for each respective period: As of December 31, 2020 2019 2018 2017 Cash and cash equivalents $ 117,890,240 $ 65,249,072 $ 100,652,809 $ 19,857,833 Restricted cash - short-term — 95,737,862 11,452,078 10,701,305 Restricted cash - long-term — — 68,292,023 6,542,448 Cash, cash equivalents and restricted cash $ 117,890,240 $ 160,986,934 $ 180,396,910 $ 37,101,586 Concentration of Credit Risk The Company has cash in bank accounts that exceeds the Federal Deposit Insurance Corporation insured limits. The Company has not no Accounts Receivable Accounts receivable are recorded net of provisions for doubtful accounts. At December 31, 2020 2019 December 31, 2020 2019 Inventory Inventory is stated at the lower of cost or net realizable value. The Company capitalizes inventory costs associated with the Company’s products when, based on management’s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are expensed as research and development. Inventory is evaluated for impairment periodically to identify inventory that may no Property, Plant and Equipment Property, plant and equipment are stated at cost, net of accumulated depreciation. Depreciation is provided on a straight-line method over the estimated useful lives of the various asset classes. The estimated useful lives are as follows: five three seven Warrant Liability The Company accounts for warrants in accordance with the authoritative guidance which requires that free-standing derivative financial instruments with certain cash settlement features be classified as assets or liabilities at the time of the transaction, and recorded at their fair value. Fair value is estimated using model-derived valuations. Any changes in the fair value of the derivative instruments are reported in earnings or loss as long as the derivative contracts are classified as assets or liabilities. Revenue Recognition All of the Company’s revenue is derived from long-term contracts that span multiple years. The Company accounts for revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers 606” Adoption of ASC 606 January 1, 2018, 606 not January 1, 2018. The cumulative impact of adopting ASC 606 January 1, 2018 December 31, 2018, 606 Performance Obligations 606. December 31, 2020 Note 3 six one one Contract modifications may not The Company’s performance obligations are satisfied over time as work progresses or at a point in time. All of the Company’s revenue related to current research and development performance obligations is recognized over time, because the customer simultaneously receives and consumes the benefits provided by the services as the Company performs these services. The Company recognizes revenue related to these services based on the progress toward complete satisfaction of the performance obligation and measures this progress under an input method, which is based on the Company’s cost incurred relative to total estimated costs. Under this method, progress is measured based on the cost of resources consumed (i.e., cost of third third Revenue connected with the performance obligations related to the delivery of oral TPOXX® to the U.S. Strategic National Stockpile ("Strategic Stockpile") ("Delivery Performance Obligation") is recognized at a point in time. The Delivery Performance Obligation under the 2011 Note 3 July 13, 2018. 3 not no Contract Estimates Contract estimates are based on various assumptions to project the outcome of future events that often span multiple years. These assumptions include labor productivity; the complexity of the work to be performed; external factors such as customer behavior and potential regulatory outcomes; and the performance of subcontractors, among other variables. The nature of the work required to be performed on many of the Company’s performance obligations and the estimation of total revenue and cost at completion are complex, subject to many variables and require significant judgment. The consideration associated with research and development services is variable as the total amount of services to be performed has not not A significant change in one As discussed in Note 3, December 31, 2019, 3 Contract Balances may December 31, 2020 December 31, 2020 Remaining Performance Obligations not December 31, 2020 five Leases The Company accounts for leases in accordance with ASC 842, Leases 842” Adoption of ASC 842 January 1, 2019, 842 first second 2019, first 842 January 1, 2019 The Company determines if an arrangement is a lease at inception. Leases with an initial term less than one not one Operating lease liabilities are recognized at the commencement date based on the present value of future minimum lease payments over the lease term. ROU assets are recognized based on the corresponding lease liabilities adjusted for qualifying initial direct costs, prepaid or accrued lease payments and unamortized lease incentives. The Company has lease agreements with lease and non-lease components, which are accounted for as a single lease. Lease terms may Research and Development Research and development expenses include costs directly and indirectly attributable to the conduct of research and development programs, and performance pursuant to the BARDA contracts, including employee related costs, materials, supplies, depreciation on and maintenance of equipment, the cost of services provided by outside contractors, including services related to the Company’s clinical trials and facility costs, such as rent, utilities, and general support services. All costs associated with research and development are expensed as incurred. Costs related to the acquisition of technology rights, for which development work is still in process, and that have no Goodwill The Company evaluates goodwill for impairment at least annually or as circumstances warrant. The impairment review process compares the fair value of the reporting unit in which goodwill resides to its carrying value. The Company operates as one business and one reporting unit. Therefore, the goodwill impairment analysis is performed on the basis of the Company as a whole, using the market capitalization of the Company as an estimate of its fair value. Share-based Compensation Stock-based compensation expense for all share-based payment awards made to employees and directors is determined on the grant date; for options awards, fair value was estimated using the Black-Scholes model. These compensation costs are recognized net of an estimated forfeiture rate over the requisite service periods of the awards. Forfeitures are estimated on the date of the respective grant and revised if actual or expected forfeiture activity differs from original estimates. Income Taxes The Company recognizes income taxes utilizing the asset and liability method of accounting for income taxes. Under this method, deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities at enacted tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is established if it is more likely than not not may not fifty not Repurchase of shares When shares recognized as equity are repurchased, the amount of the consideration paid, which includes directly attributable costs, is recognized as a deduction from equity. The excess of the purchase price above par value of repurchased shares that are retired is presented as an increase to accumulated deficit (or a reduction of retained earnings, if any). (Loss) Earnings per Share Basic earnings per share is computed by dividing net (loss) income by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing net (loss) income by the weighted-average number of common shares outstanding during the period, assuming potentially dilutive common shares from option exercises, SSARs, RSUs, warrants and other incentives had been issued and any proceeds received in respect thereof were used to repurchase common stock at the average market price during the period. The assumed proceeds used to repurchase common stock is the sum of the amount to be paid to the Company upon exercise of options and the amount of compensation cost attributed to future services not Fair Value of Financial Instruments The carrying value of cash and cash equivalents, restricted cash and cash equivalents, accounts receivable, accounts payable and accrued expenses and other current liabilities approximates fair value due to the relatively short maturity of these instruments. Common stock warrants which are classified as liabilities are recorded at their fair market value as of each reporting period. The measurement of fair value requires the use of techniques based on observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our market assumptions. The inputs create the following fair value hierarchy: • Level 1 • Level 2 not • Level 3 third The Company uses model-derived valuations where certain inputs are unobservable to third 3. The Company used a discounted cash flow model to estimate the fair value of the debt by applying a discount rate to future payments expected to be made as set forth in the Loan Agreement. The fair value of the loan was measured using Level 3 There were no 2020 2019 December 31, 2020 1 no 2 December 31, 2020 December 31, 2019 1 2 The following table presents changes in the liability-classified warrant measured at fair value using Level 3 Fair Value Measurements of Level 3 liability-classified warrant Warrant liability at December 31, 2019 $ 6,116,882 Increase in fair value of warrant liability 3,525,846 Exercise of warrants (3,003,517 ) Warrant liability at December 31, 2020 $ 6,639,211 Loss Contingencies The Company is subject to certain contingencies arising in the ordinary course of business. The Company records accruals for these contingencies to the extent that a loss is both probable and reasonably estimable. If some amount within a range of loss appears to be a better estimate than any other amount within the range, that amount is accrued. Alternatively, when no Segment Information The Company is managed and operated as one not not Recent Accounting Pronouncements In June 2016, No. 2016 13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments 2016 13" 2016 13 December 15, 2019, no In December 2019, No. 2019 12, Simplifying the Accounting for Income Taxes December 15, 2020, not

Note 3 - Procurement Contract a

Note 3 - Procurement Contract and Research Agreements	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Procurement Contract and Research Agreements [Text Block]	3. 19C On September 10, 2018, December 31, 2020, "19C five may ten 19C The base period of performance specifies potential payments of approximately $51.7 million for the following activities: payments of approximately $11.1 million for the delivery of approximately 35,700 courses of oral TPOXX® to the Strategic Stockpile; payments of $8.0 million for the manufacture of 20,000 courses of final drug product of IV TPOXX® ("IV FDP"), of which $3.2 million of payments are related to the manufacture of bulk drug substance ("IV BDS") to be used in the manufacture of IV FDP; payments of approximately $32.0 million to fund advanced development of IV TPOXX®; and payments of approximately $0.6 million for supportive procurement activities. As of December 31, 2020, December 31, 2020 December 31, 2019; The options that have been exercised to date provide for payments up to approximately $127.1 million. There are exercised options for the following activities: payments up to $11.2 million for the procurement of raw materials to be used in the manufacture of at least 363,070 December 31, 2020, December 31, 2020, June, September October 363,000 Unexercised options specify potential payments up to approximately $423.7 million in total (if all such options are exercised). There are options for the following activities: payments of up to $337.7 million for the delivery of up to approximately 1,089,000 courses of oral TPOXX® to the Strategic Stockpile; payments of up to $76.8 million for the manufacture of up to 192,000 courses of IV FDP, of which up to $30.7 million of payments would be paid upon the manufacture of IV BDS to be used in the manufacture of IV FDP; payments of up to approximately $3.6 million to fund post-marketing activities for IV TPOXX®; and payments of up to approximately $5.6 million for supportive procurement activities. The options related to IV TPOXX® are divided into two may none 19C three three not 64,000 Revenues in connection with the 19C 19C December 31, 2020 2019 December 31, 2020 2019 2011 On May 13, 2011, no The contract with BARDA (as amended, modified, or supplemented from time to time the "2011 "2011 2011 December 31, 2020 For courses of oral TPOXX® that have been physically delivered to the Strategic Stockpile under the 2011 no not July 13, 2018, no The 2011 July 30, 2018, 2011 August 2018. 2011 2011 may not 2015, two The 2011 December 2024. As described in Note 2, 2011 third 2018. third 2018, 2011 December 31, 2018. third 2018 2011 84 2011 December 31, 2017, 2011 third 2018. Revenues in connection with the 2011 2011 December 31, 2020 2019 December 31, 2020 2019 International Procurement Contracts On January 13, 2021, five March 31, 2021 March 31, 2023; March 31, 2023 not On April 3, 2020, four second 2020, The PHAC and CDND contract awards were both coordinated between SIGA and Meridian under the international promotion agreement, as amended (the "International Promotion Agreement") that was entered into by the parties on June 3, 2019. Under the terms of the International Promotion Agreement, Meridian was granted exclusive rights to market, advertise, promote, offer for sale, or sell oral TPOXX® in a field of use specified in the International Promotion Agreement in all geographic regions except for the United States (the “Territory”), and Meridian has agreed not The fee Meridian retains pursuant to the International Promotion Agreement will be a specified percentage of the collected proceeds of sales of oral TPOXX® net of certain expenses, for years in which customer invoiced amounts net of such expenses are less than or equal to a specified threshold, and a higher specified percentage of such collected net proceeds for years in which such net invoiced amounts exceed the specified threshold. Revenue in connection with international procurement contracts for the delivery of product are recognized at a point in time. During the year ended December 31, 2020 Research Agreements and Grants The Company has an R&D program for IV TPOXX®. This program is funded by the 19C February 2024. December 31, 2020 Revenues in connection with the IV Formulation R&D Contract are recognized over time. For the years ended December 31, 2020 2019 December 31, 2019, not January 2016 March 2019. In July 2019, May 2020, December 31, 2020 July 31, 2025. December 31, 2020 2019 Contracts and grants include, among other things, options that may may not may not

Note 4 - Sale of Priority Revie

Note 4 - Sale of Priority Review Voucher	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Sale of Priority Review Voucher [Text Block]	4. Concurrent with the approval of oral TPOXX®, the FDA granted the Company's request for a Priority Review Voucher (“PRV”). A PRV is a voucher that may October 31, 2018

Note 5 - Inventory

Note 5 - Inventory	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Inventory Disclosure [Text Block]	5. Inventory Inventory consisted of the following: As of December 31, 2020 December 31, 2019 Raw materials $ 2,628,153 $ — Work in-process 15,415,425 8,693,457 Finished goods 2,221,941 959,398 Inventory $ 20,265,519 $ 9,652,855

Note 6 - Property, Plant and Eq

Note 6 - Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	6. Property, Plant and Equipment Property, plant and equipment consisted of the following: As of December 31, 2020 December 31, 2019 Leasehold improvements $ 2,420,028 $ 2,420,028 Computer equipment 532,125 601,797 Furniture and fixtures 377,859 377,859 Operating lease right-of-use asset 2,944,932 2,944,932 6,274,944 6,344,616 Less-accumulated depreciation (4,170,954 ) (3,726,313 ) Property, plant and equipment, net $ 2,103,990 $ 2,618,303 Depreciation and amortization expense on property, plant, and equipment was $529,814, $526,997, and $69,630 for the years ended December 31, 2020 2019 2018

Note 7 - Accrued Expenses

Note 7 - Accrued Expenses	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Accrued Expenses and Other Liabilities [Text Block]	7. Accrued Expenses Accrued expenses and other current liabilities consisted of the following: As of December 31, 2020 December 31, 2019 Deferred revenue $ 3,280,947 $ 2,298,341 Compensation 2,933,738 2,966,139 Lease liability, current portion 449,940 419,709 Other 486,158 643,570 Vacation 405,176 256,402 Research and development vendor costs 327,606 707,685 Professional fees 251,824 288,707 Inventory 150,349 71,541 Interest payable — 977,724 Income tax payable 919,555 7,093 Accrued expenses and other current liabilities $ 9,205,293 $ 8,636,911

Note 8 - Debt

Note 8 - Debt	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Debt Disclosure [Text Block]	8. On March 13, 2020, December 31, 2020 On September 2, 2016, November 16, 2016 September 30, 2016 ( November 16, 2016), not not no no November 16, 2016. The Term Loan had a maturity date on the earliest to occur of (i) the four Through the three one May 17, 2020) In connection with the issuance of the Loan Agreement, the Company incurred $8.2 million of costs (including interest on amounts held in the escrow account between September 30, 2016 November 15, 2016). $4.0 10 not

Note 9 - Per Share Data

Note 9 - Per Share Data	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Earnings Per Share [Text Block]	9. Per Share Data The Company computes, presents and discloses earnings per share in accordance with the authoritative guidance which specifies the computation, presentation and disclosure requirements for earnings per share of entities with publicly held common stock or potential common stock. The objective of basic EPS is to measure the performance of an entity over the reporting period by dividing income (loss) by the weighted average shares outstanding. The objective of diluted EPS is consistent with that of basic EPS, except that it also gives effect to all potentially dilutive common shares outstanding during the period. The following is a reconciliation of the basic and diluted (loss) earnings per share computation: Year Ended December 31, 2020 2019 2018 Net income (loss) for basic earnings per share $ 56,342,010 $ (7,241,147 ) $ 421,807,828 Less: Change in fair value of warrants — 5,091,256 (6,922,624 ) Net income (loss), adjusted for change in fair value of warrants for diluted earnings per share $ 56,342,010 $ (12,332,403 ) $ 428,730,452 Weighted-average shares 79,259,000 81,031,254 79,923,295 Effect of potential common shares 178,306 1,143,769 2,785,177 Weighted-average shares: diluted 79,437,306 82,175,023 82,708,472 Earnings (loss) per share: basic $ 0.71 $ (0.09 ) $ 5.28 Earnings (loss) per share: diluted $ 0.71 $ (0.15 ) $ 5.18 For the year ended December 31, 2020 not December 31, 2020 December 31, 2020 The Company incurred losses for the twelve December 31, 2019 Year Ended December 31, 2019 Stock Options 340,284 Stock-Settled Stock Appreciation Rights 1,666 Restricted Stock Units 525,741

Note 10 - Financial Instruments

Note 10 - Financial Instruments	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Financial Instruments Disclosure [Text Block]	10. 2016 On September 2, 2016, Note 8 Note 11 December 31, 2020 December 31, 2020 ten The Company accounted for the Warrant in accordance with the authoritative guidance which requires that free-standing derivative financial instruments with certain anti-dilution and cash settlement features be classified as assets or liabilities at the time of the transaction, and recorded at their fair value. Any changes in the fair value of the derivative instruments are reported in earnings or loss as long as the derivative contracts are classified as assets or liabilities. Accordingly, the Company classified the Warrant as a liability and reports its change in fair value in the consolidated statement of operations. On September 2, 2016, December 31, 2016. December 31, 2020 2019 As of December 31, 2020 As of December 31, 2019 1.81%; At December 31, 2020 no

Note 11 - Stockholders' Equity

Note 11 - Stockholders' Equity	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	11. Stockholders’ Equity On December 31, 2020 December 31, 2020 2019 On March 5, 2020, may December 31, 2021. may may 10b5 1 1934, December 31, 2020

Note 12 - Stock Compensation Pl

Note 12 - Stock Compensation Plans	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	12. Stock Compensation Plans The Company’s 2010 “2010 May 2010. 2010 May 17, 2011, 2010 February 2, 2012, 2010 April 25, 2012 May 23, 2017, 2010 2010 may not ten 2010 ten For the years ended December 31, 2020, 2019 2018 Stock Options Stock option awards provide holders the right to purchase shares of Common Stock at prices determined by the Compensation Committee, at the time of grant, and must have an exercise price equal to or in excess of the fair market value of the Company’s common stock at the date of grant. The fair value of options granted is estimated at the date of grant. Expected volatility has been estimated using a combination of the historical volatility of the Company's common stock and the historical volatility of a group of comparable companies’ common stock, both using historical periods equivalent to the options’ expected lives. The expected dividend yield assumption is based on the Company’s intent not A summary of the Company’s stock option activity is as follows: Weighted Weighted Aggregate Average Average Intrinsic Number of Exercise Remaining Life Value Options Price (in years) (in thousands) Outstanding at January 1, 2020 281,000 $ 9.68 Granted 75,000 6.47 Exercised (25,000 ) 3.89 Canceled/Expired (78,000 ) 8.13 Outstanding at December 31, 2020 253,000 $ 9.78 3.47 $ 170,000 Vested at December 31, 2020 253,000 $ 9.78 3.47 $ 170,000 Exercisable at December 31, 2020 253,000 $ 9.78 3.47 $ 170,000 As of December 31, 2020 December 31, 2020 2019 December 31, 2019 The total intrinsic value of stock options exercised was approximately $87,000, $76,000 and $2,900,000 for the years ended December 31, 2020, 2019 2018 Restricted Stock Awards/Restricted Stock Units RSUs awarded to employees vest in equal annual installments over a two three one Weighted Average Number of Grant-Date RSUs Fair Value Outstanding at January 1, 2020 240,292 $ 5.83 Granted 135,000 5.95 Vested and released (177,876 ) 5.84 Canceled/Expired (30,000 ) 6.20 Outstanding at December 31, 2020 167,416 $ 5.86 As of December 31, 2020 December 31, 2020 2019 2018 December 31, 2020, 2019 2018

Note 13 - Income Taxes

Note 13 - Income Taxes	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Income Tax Disclosure [Text Block]	13. Income Taxes The Company's provision (benefit) for income taxes comprises the following: For the year ended December 31, 2020 2019 2018 Current: Federal $ 5,111,667 $ (663,114 ) $ (1,326,022 ) State and local 447,965 143,455 459,172 Total current provision (benefit) 5,559,632 (519,659 ) (866,850 ) Deferred: Federal 11,375,962 (2,092,585 ) (9,256,661 ) State and local 230,987 (325,032 ) (44,761 ) Total deferred provision (benefit) 11,606,949 (2,417,617 ) (9,301,422 ) Total provision (benefit) $ 17,166,581 $ (2,937,276 ) $ (10,168,272 ) The Company’s deferred tax assets and liabilities comprise the following: As of December 31, 2020 2019 Deferred income tax assets: Net operating losses $ 1,293,842 $ 9,353,603 Amortization of intangible assets 80,930 113,910 Share-based compensation 398,165 451,818 Deferred revenue 709,480 719,304 Interest expense carryforward — 2,617,951 Lease liability 520,830 678,993 Alternative minimum tax credits — 663,114 Other 1,141,705 1,338,046 Deferred income tax assets 4,144,952 15,936,739 Less: valuation allowance (1,022,135 ) (1,047,008 ) Deferred income tax assets, net of valuation allowance $ 3,122,817 $ 14,889,731 Deferred income tax liabilities: Amortization of goodwill (199,172 ) (201,930 ) Property, plant and equipment (81,065 ) (175,581 ) Other (298,527 ) (361,218 ) Deferred income tax asset, net $ 2,544,053 $ 14,151,002 The recognition of a valuation allowance for deferred taxes requires management to make estimates and judgments about the Company’s future profitability which is inherently uncertain. The Company assesses all available positive and negative evidence to determine if its existing deferred tax assets are realizable on a more-likely-than- not December 31, 2020 2019 not not December 31, 2020. The benefit for income taxes differs from the expected amount calculated by applying the Company's statutory rate to the income or loss before benefit for income taxes as follows: As of December 31, 2020 2019 2018 Statutory federal income tax rate 21.0 % 21.0 % 21.0 % State and local taxes 0.7 % 1.3 % 0.8 % Change in fair value of common stock warrant 1.0 % 10.5 % 0.4 % Section 162(m) limitation 0.5 % (6.0 )% 0.3 % Other 0.2 % 2.1 % (0.3 )% Valuation allowance on deferred tax assets — — (24.7 )% Effective tax rate 23.4 % 28.9 % (2.5 )% For the year ended December 31, 2020 162 December 31, 2019 162 A reconciliation of the beginning and ending amount of unrecognized tax benefits, excluding interest and penalties, is as follows: For the year ended December 31, 2020 2019 2018 Balance at beginning of year $ 5,649,188 $ 5,738,964 $ — Tax positions related to the current and prior years: — — — Additions — — 5,738,964 Reductions (57,601 ) (89,776 ) — Settlements — — — Lapses in applicable statutes of limitation — — — Balance at the end of the year $ 5,591,587 $ 5,649,188 $ 5,738,964 Included in the balance of unrecognized tax benefits as of December 31, 2020 December 31, 2020 December 31, 2019 no twelve December 31, 2020 The Company files federal income tax returns and income tax returns in various state and local tax jurisdictions. The federal tax years open to examination are 2017 2020 2016 2020

Note 14 - Commitments and Conti

Note 14 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	14. Commitments and Contingencies Operating lease commitments The Company leases its Corvallis, Oregon, facilities and office space under an operating lease which was signed on November 3, 2017 January 1, 2018. December 31, 2021. May 26, 2017 ten 31 62nd no Operating lease costs totaled $0.7 million and $0.6 million for the years ended December 31, 2020 2019 December 31, 2020 2019 December 31, 2020 The following is a maturity analysis of the Company's lease liabilities as of December 31, 2020 2021 550,904 2022 368,467 2023 402,078 2024 404,258 2025 406,994 Thereafter 575,887 Total undiscounted cash flows under operating leases 2,708,588 Less: Imputed interest (359,467 ) Present value of lease liabilities $ 2,349,121 As of December 31, 2020 Legal Proceedings From time to time, we may not Purchase Commitments In the course of our business, the Company regularly enters into agreements with third not December 31, 2020

Note 15 - Related Party Transac

Note 15 - Related Party Transactions	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	15. Related Party Transactions Board of Directors and Outside Counsel A member of the Company’s Board of Directors is a member of the Company’s outside counsel. During the years ended December 31, 2020, 2019 2018 December 31, 2020 Board of Directors-Consulting Agreement On October 13, 2018, October 13, 2020 not December 31, 2020 December 31, 2020 Real Estate Leases On May 26, 2017 31 62nd first sixty-three first six first sixty-fourth first second five On July 31, 2017, January 9, 2013 660 1700, Effectiveness of the Old HQ Sublease Termination Agreement was conditioned upon the commencement of a sublease for the Old HQ between M&F and a new subtenant (the “Replacement M&F Sublease”), which occurred on August 2, 2017. Under the Old HQ Sublease, the Company was obligated to pay fixed rent of approximately $60,000 per month until August 2018 September 2020. 660 Under the Replacement M&F Sublease, the subtenant’s rental obligations were excused for the first two 2 first twelve 12 12 September, 2020.

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of Estimates Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the periods reported. The most significant estimates include the variables used in the calculation of fair value of warrants granted or issued by the Company, reported amounts of revenue, and the valuation of deferred tax assets. Estimates and assumptions are reviewed periodically and the effects of revisions are reflected in the financial statements in the period they are determined to be necessary. Actual results could differ from these estimates.
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The consolidated financial statements and related disclosures are presented in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) and reflect the consolidated financial position, results of operations and cash flows for all periods presented.
Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]	Cash Equivalents The Company considers all highly liquid investments with original maturities of three
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]	Restricted Cash and Cash Equivalents Under the terms of the Loan Agreement (as defined below), net cash proceeds from the Company's Priority Review Voucher ("PRV") sale on October 31, 2018 ( 4 8 second 2020 second 2020 The following table reconciles cash, cash equivalents and restricted cash per the consolidated statements of cash flows to the consolidated balance sheet for each respective period: As of December 31, 2020 2019 2018 2017 Cash and cash equivalents $ 117,890,240 $ 65,249,072 $ 100,652,809 $ 19,857,833 Restricted cash - short-term — 95,737,862 11,452,078 10,701,305 Restricted cash - long-term — — 68,292,023 6,542,448 Cash, cash equivalents and restricted cash $ 117,890,240 $ 160,986,934 $ 180,396,910 $ 37,101,586
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk The Company has cash in bank accounts that exceeds the Federal Deposit Insurance Corporation insured limits. The Company has not no
Accounts Receivable [Policy Text Block]	Accounts Receivable Accounts receivable are recorded net of provisions for doubtful accounts. At December 31, 2020 2019 December 31, 2020 2019
Inventory, Policy [Policy Text Block]	Inventory Inventory is stated at the lower of cost or net realizable value. The Company capitalizes inventory costs associated with the Company’s products when, based on management’s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are expensed as research and development. Inventory is evaluated for impairment periodically to identify inventory that may no
Property, Plant and Equipment, Policy [Policy Text Block]	Property, Plant and Equipment Property, plant and equipment are stated at cost, net of accumulated depreciation. Depreciation is provided on a straight-line method over the estimated useful lives of the various asset classes. The estimated useful lives are as follows: five three seven
Derivatives, Policy [Policy Text Block]	Warrant Liability The Company accounts for warrants in accordance with the authoritative guidance which requires that free-standing derivative financial instruments with certain cash settlement features be classified as assets or liabilities at the time of the transaction, and recorded at their fair value. Fair value is estimated using model-derived valuations. Any changes in the fair value of the derivative instruments are reported in earnings or loss as long as the derivative contracts are classified as assets or liabilities.
Revenue [Policy Text Block]	Revenue Recognition All of the Company’s revenue is derived from long-term contracts that span multiple years. The Company accounts for revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers 606” Adoption of ASC 606 January 1, 2018, 606 not January 1, 2018. The cumulative impact of adopting ASC 606 January 1, 2018 December 31, 2018, 606 Performance Obligations 606. December 31, 2020 Note 3 six one one Contract modifications may not The Company’s performance obligations are satisfied over time as work progresses or at a point in time. All of the Company’s revenue related to current research and development performance obligations is recognized over time, because the customer simultaneously receives and consumes the benefits provided by the services as the Company performs these services. The Company recognizes revenue related to these services based on the progress toward complete satisfaction of the performance obligation and measures this progress under an input method, which is based on the Company’s cost incurred relative to total estimated costs. Under this method, progress is measured based on the cost of resources consumed (i.e., cost of third third Revenue connected with the performance obligations related to the delivery of oral TPOXX® to the U.S. Strategic National Stockpile ("Strategic Stockpile") ("Delivery Performance Obligation") is recognized at a point in time. The Delivery Performance Obligation under the 2011 Note 3 July 13, 2018. 3 not no Contract Estimates Contract estimates are based on various assumptions to project the outcome of future events that often span multiple years. These assumptions include labor productivity; the complexity of the work to be performed; external factors such as customer behavior and potential regulatory outcomes; and the performance of subcontractors, among other variables. The nature of the work required to be performed on many of the Company’s performance obligations and the estimation of total revenue and cost at completion are complex, subject to many variables and require significant judgment. The consideration associated with research and development services is variable as the total amount of services to be performed has not not A significant change in one As discussed in Note 3, December 31, 2019, 3 Contract Balances may December 31, 2020 December 31, 2020 Remaining Performance Obligations not December 31, 2020 five
Lessee, Leases [Policy Text Block]	Leases The Company accounts for leases in accordance with ASC 842, Leases 842” Adoption of ASC 842 January 1, 2019, 842 first second 2019, first 842 January 1, 2019 The Company determines if an arrangement is a lease at inception. Leases with an initial term less than one not one Operating lease liabilities are recognized at the commencement date based on the present value of future minimum lease payments over the lease term. ROU assets are recognized based on the corresponding lease liabilities adjusted for qualifying initial direct costs, prepaid or accrued lease payments and unamortized lease incentives. The Company has lease agreements with lease and non-lease components, which are accounted for as a single lease. Lease terms may
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development expenses include costs directly and indirectly attributable to the conduct of research and development programs, and performance pursuant to the BARDA contracts, including employee related costs, materials, supplies, depreciation on and maintenance of equipment, the cost of services provided by outside contractors, including services related to the Company’s clinical trials and facility costs, such as rent, utilities, and general support services. All costs associated with research and development are expensed as incurred. Costs related to the acquisition of technology rights, for which development work is still in process, and that have no
Goodwill and Intangible Assets, Policy [Policy Text Block]	Goodwill The Company evaluates goodwill for impairment at least annually or as circumstances warrant. The impairment review process compares the fair value of the reporting unit in which goodwill resides to its carrying value. The Company operates as one business and one reporting unit. Therefore, the goodwill impairment analysis is performed on the basis of the Company as a whole, using the market capitalization of the Company as an estimate of its fair value.
Share-based Payment Arrangement [Policy Text Block]	Share-based Compensation Stock-based compensation expense for all share-based payment awards made to employees and directors is determined on the grant date; for options awards, fair value was estimated using the Black-Scholes model. These compensation costs are recognized net of an estimated forfeiture rate over the requisite service periods of the awards. Forfeitures are estimated on the date of the respective grant and revised if actual or expected forfeiture activity differs from original estimates.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company recognizes income taxes utilizing the asset and liability method of accounting for income taxes. Under this method, deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities at enacted tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is established if it is more likely than not not may not fifty not
Stockholders' Equity, Policy [Policy Text Block]	Repurchase of shares When shares recognized as equity are repurchased, the amount of the consideration paid, which includes directly attributable costs, is recognized as a deduction from equity. The excess of the purchase price above par value of repurchased shares that are retired is presented as an increase to accumulated deficit (or a reduction of retained earnings, if any).
Earnings Per Share, Policy [Policy Text Block]	(Loss) Earnings per Share Basic earnings per share is computed by dividing net (loss) income by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing net (loss) income by the weighted-average number of common shares outstanding during the period, assuming potentially dilutive common shares from option exercises, SSARs, RSUs, warrants and other incentives had been issued and any proceeds received in respect thereof were used to repurchase common stock at the average market price during the period. The assumed proceeds used to repurchase common stock is the sum of the amount to be paid to the Company upon exercise of options and the amount of compensation cost attributed to future services not
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments The carrying value of cash and cash equivalents, restricted cash and cash equivalents, accounts receivable, accounts payable and accrued expenses and other current liabilities approximates fair value due to the relatively short maturity of these instruments. Common stock warrants which are classified as liabilities are recorded at their fair market value as of each reporting period. The measurement of fair value requires the use of techniques based on observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our market assumptions. The inputs create the following fair value hierarchy: • Level 1 • Level 2 not • Level 3 third The Company uses model-derived valuations where certain inputs are unobservable to third 3. The Company used a discounted cash flow model to estimate the fair value of the debt by applying a discount rate to future payments expected to be made as set forth in the Loan Agreement. The fair value of the loan was measured using Level 3 There were no 2020 2019 December 31, 2020 1 no 2 December 31, 2020 December 31, 2019 1 2 The following table presents changes in the liability-classified warrant measured at fair value using Level 3 Fair Value Measurements of Level 3 liability-classified warrant Warrant liability at December 31, 2019 $ 6,116,882 Increase in fair value of warrant liability 3,525,846 Exercise of warrants (3,003,517 ) Warrant liability at December 31, 2020 $ 6,639,211
Commitments and Contingencies, Policy [Policy Text Block]	Loss Contingencies The Company is subject to certain contingencies arising in the ordinary course of business. The Company records accruals for these contingencies to the extent that a loss is both probable and reasonably estimable. If some amount within a range of loss appears to be a better estimate than any other amount within the range, that amount is accrued. Alternatively, when no
Segment Reporting, Policy [Policy Text Block]	Segment Information The Company is managed and operated as one not not
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In June 2016, No. 2016 13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments 2016 13" 2016 13 December 15, 2019, no In December 2019, No. 2019 12, Simplifying the Accounting for Income Taxes December 15, 2020, not

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Cash, Cash Equivalents and Investments [Table Text Block]	As of December 31, 2020 2019 2018 2017 Cash and cash equivalents $ 117,890,240 $ 65,249,072 $ 100,652,809 $ 19,857,833 Restricted cash - short-term — 95,737,862 11,452,078 10,701,305 Restricted cash - long-term — — 68,292,023 6,542,448 Cash, cash equivalents and restricted cash $ 117,890,240 $ 160,986,934 $ 180,396,910 $ 37,101,586
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Fair Value Measurements of Level 3 liability-classified warrant Warrant liability at December 31, 2019 $ 6,116,882 Increase in fair value of warrant liability 3,525,846 Exercise of warrants (3,003,517 ) Warrant liability at December 31, 2020 $ 6,639,211

Note 5 - Inventory (Tables)

Note 5 - Inventory (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Inventory, Current [Table Text Block]	As of December 31, 2020 December 31, 2019 Raw materials $ 2,628,153 $ — Work in-process 15,415,425 8,693,457 Finished goods 2,221,941 959,398 Inventory $ 20,265,519 $ 9,652,855

Note 6 - Property, Plant and _2

Note 6 - Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Property, Plant and Equipment [Table Text Block]	As of December 31, 2020 December 31, 2019 Leasehold improvements $ 2,420,028 $ 2,420,028 Computer equipment 532,125 601,797 Furniture and fixtures 377,859 377,859 Operating lease right-of-use asset 2,944,932 2,944,932 6,274,944 6,344,616 Less-accumulated depreciation (4,170,954 ) (3,726,313 ) Property, plant and equipment, net $ 2,103,990 $ 2,618,303

Note 7 - Accrued Expenses (Tabl

Note 7 - Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Accrued Expenses and Other Current Liabilities [Table Text Block]	As of December 31, 2020 December 31, 2019 Deferred revenue $ 3,280,947 $ 2,298,341 Compensation 2,933,738 2,966,139 Lease liability, current portion 449,940 419,709 Other 486,158 643,570 Vacation 405,176 256,402 Research and development vendor costs 327,606 707,685 Professional fees 251,824 288,707 Inventory 150,349 71,541 Interest payable — 977,724 Income tax payable 919,555 7,093 Accrued expenses and other current liabilities $ 9,205,293 $ 8,636,911

Note 9 - Per Share Data (Tables

Note 9 - Per Share Data (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Year Ended December 31, 2020 2019 2018 Net income (loss) for basic earnings per share $ 56,342,010 $ (7,241,147 ) $ 421,807,828 Less: Change in fair value of warrants — 5,091,256 (6,922,624 ) Net income (loss), adjusted for change in fair value of warrants for diluted earnings per share $ 56,342,010 $ (12,332,403 ) $ 428,730,452 Weighted-average shares 79,259,000 81,031,254 79,923,295 Effect of potential common shares 178,306 1,143,769 2,785,177 Weighted-average shares: diluted 79,437,306 82,175,023 82,708,472 Earnings (loss) per share: basic $ 0.71 $ (0.09 ) $ 5.28 Earnings (loss) per share: diluted $ 0.71 $ (0.15 ) $ 5.18
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Year Ended December 31, 2019 Stock Options 340,284 Stock-Settled Stock Appreciation Rights 1,666 Restricted Stock Units 525,741

Note 12 - Stock Compensation _2

Note 12 - Stock Compensation Plans (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Weighted Weighted Aggregate Average Average Intrinsic Number of Exercise Remaining Life Value Options Price (in years) (in thousands) Outstanding at January 1, 2020 281,000 $ 9.68 Granted 75,000 6.47 Exercised (25,000 ) 3.89 Canceled/Expired (78,000 ) 8.13 Outstanding at December 31, 2020 253,000 $ 9.78 3.47 $ 170,000 Vested at December 31, 2020 253,000 $ 9.78 3.47 $ 170,000 Exercisable at December 31, 2020 253,000 $ 9.78 3.47 $ 170,000
Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]	Weighted Average Number of Grant-Date RSUs Fair Value Outstanding at January 1, 2020 240,292 $ 5.83 Granted 135,000 5.95 Vested and released (177,876 ) 5.84 Canceled/Expired (30,000 ) 6.20 Outstanding at December 31, 2020 167,416 $ 5.86

Note 13 - Income Taxes (Tables)

Note 13 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	For the year ended December 31, 2020 2019 2018 Current: Federal $ 5,111,667 $ (663,114 ) $ (1,326,022 ) State and local 447,965 143,455 459,172 Total current provision (benefit) 5,559,632 (519,659 ) (866,850 ) Deferred: Federal 11,375,962 (2,092,585 ) (9,256,661 ) State and local 230,987 (325,032 ) (44,761 ) Total deferred provision (benefit) 11,606,949 (2,417,617 ) (9,301,422 ) Total provision (benefit) $ 17,166,581 $ (2,937,276 ) $ (10,168,272 )
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	As of December 31, 2020 2019 Deferred income tax assets: Net operating losses $ 1,293,842 $ 9,353,603 Amortization of intangible assets 80,930 113,910 Share-based compensation 398,165 451,818 Deferred revenue 709,480 719,304 Interest expense carryforward — 2,617,951 Lease liability 520,830 678,993 Alternative minimum tax credits — 663,114 Other 1,141,705 1,338,046 Deferred income tax assets 4,144,952 15,936,739 Less: valuation allowance (1,022,135 ) (1,047,008 ) Deferred income tax assets, net of valuation allowance $ 3,122,817 $ 14,889,731 Deferred income tax liabilities: Amortization of goodwill (199,172 ) (201,930 ) Property, plant and equipment (81,065 ) (175,581 ) Other (298,527 ) (361,218 ) Deferred income tax asset, net $ 2,544,053 $ 14,151,002
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	As of December 31, 2020 2019 2018 Statutory federal income tax rate 21.0 % 21.0 % 21.0 % State and local taxes 0.7 % 1.3 % 0.8 % Change in fair value of common stock warrant 1.0 % 10.5 % 0.4 % Section 162(m) limitation 0.5 % (6.0 )% 0.3 % Other 0.2 % 2.1 % (0.3 )% Valuation allowance on deferred tax assets — — (24.7 )% Effective tax rate 23.4 % 28.9 % (2.5 )%
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]	For the year ended December 31, 2020 2019 2018 Balance at beginning of year $ 5,649,188 $ 5,738,964 $ — Tax positions related to the current and prior years: — — — Additions — — 5,738,964 Reductions (57,601 ) (89,776 ) — Settlements — — — Lapses in applicable statutes of limitation — — — Balance at the end of the year $ 5,591,587 $ 5,649,188 $ 5,738,964

Note 14 - Commitments and Con_2

Note 14 - Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	2021 550,904 2022 368,467 2023 402,078 2024 404,258 2025 406,994 Thereafter 575,887 Total undiscounted cash flows under operating leases 2,708,588 Less: Imputed interest (359,467 ) Present value of lease liabilities $ 2,349,121

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual)	Jan. 01, 2019USD ($)	Mar. 31, 2019USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Jan. 01, 2018USD ($)	Dec. 31, 2017USD ($)
Receivables Percentage			100.00%	100.00%
Accounts Receivable, Allowance for Credit Loss, Ending Balance			$ 0	$ 0
Retained Earnings (Accumulated Deficit), Ending Balance			(95,192,881)	(123,032,408)
Revenue from Contract with Customer, Excluding Assessed Tax, Total			124,959,304	26,742,085	$ 477,053,782
Contract with Customer, Receivable, after Allowance for Credit Loss, Current, Total			1,300,000
Contract with Customer, Liability, Revenue Recognized			100,000
Revenue, Remaining Performance Obligation, Amount			63,500,000
Operating Lease, Right-of-Use Asset			$ 2,944,932	2,944,932
Number of Operating Segments			1
Number of Reporting Units			1
Cash and Cash Equivalents, at Carrying Value, Ending Balance			$ 117,890,240	65,249,072	100,652,809		$ 19,857,833
Number of Reportable Segments			1
Fair Value, Inputs, Level 1 [Member]
Cash and Cash Equivalents, at Carrying Value, Ending Balance			$ 100,000
Restricted Cash and Cash Equivalents, Total				5,600,000
Fair Value, Inputs, Level 2 [Member]
Restricted Cash and Cash Equivalents, Total				90,000,000
The IV Formulation R & D Contract with BARDA [Member] | Transferred over Time [Member]
Contract with Customer, Asset, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price		$ 3,300,000		3,300,000
Contract with Customer, Liability, Revenue Recognized			$ 1,400,000	$ 7,500,000
Accounting Standards Update 2014-09 [Member]
Deferred Revenue, Total						$ 1,800,000
Deferred Costs, Total						2,100,000
Accounts Receivable, after Allowance for Credit Loss, Total						100,000
Retained Earnings (Accumulated Deficit), Ending Balance						$ 200,000
Revenue from Contract with Customer, Excluding Assessed Tax, Total					$ 1,000,000
Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset	$ 2,900,000
Operating Lease, Liability, Total	3,300,000
Increase (Decrease) in Deferred Rent	$ 400,000
Laboratory Equipment [Member]
Property, Plant and Equipment, Useful Life (Year)			5 years
Computer Equipment [Member]
Property, Plant and Equipment, Useful Life (Year)			3 years
Furniture and Fixtures [Member]
Property, Plant and Equipment, Useful Life (Year)			7 years

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Cash and cash equivalents	$ 117,890,240	$ 65,249,072	$ 100,652,809	$ 19,857,833
Restricted cash - short-term	0	95,737,862	11,452,078	10,701,305
Restricted cash - long-term	0	0	68,292,023	6,542,448
Cash, cash equivalents and restricted cash	$ 117,890,240	$ 160,986,934	$ 180,396,910	$ 37,101,586

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies - Change in Level 3 Liability (Details)	12 Months Ended
	Dec. 31, 2020USD ($)
Balance	$ 6,116,882
Increase in fair value of warrant liability	3,525,846
Exercise of warrants	(3,003,517)
Balance	$ 6,639,211

Note 3 - Procurement Contract_2

Note 3 - Procurement Contract and Research Agreements (Details Textual) $ in Millions	Apr. 03, 2020USD ($)	Jul. 30, 2018USD ($)	Aug. 31, 2018USD ($)	Mar. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Jan. 13, 2021USD ($)	Jun. 30, 2020USD ($)	May 31, 2020USD ($)	Jul. 31, 2019USD ($)	Sep. 10, 2018	Dec. 31, 2017USD ($)	May 13, 2011
Contract with Customer, Liability, Revenue Recognized						$ 0.1
The 19C BARDA Contract [Member]
Number of Courses to Be Delivered													1,488,000
Number of Courses Stored As Vendor Managed Inventory													212,000
Government Contract, Value of Award						602.5
Government Contract, Base Period, Value of Award for Delivery and Support Activities						$ 51.7
Base Period of Performance (Year)						5 years
Government Contract, Value, Payments Remaining Related to Exercised Options						$ 127.1
Government Contract, Value, Payments Currently Specified as Unexercised Options						$ 423.7
Base Period of Performance, Exercise of Options, Term (Year)						10 years
Government Contract, Base Period, Value of Award for Delivery and Support Activities, Delivery of Courses						$ 11.1
Government Contract, Base Period, Number of Deliveries						35,700
Government Contract, Base Period, Value of Award for Delivery and Support Activities, Manufacture of Courses						$ 8
Government Contract, Base Period, Value of Award for Delivery and Support Activities, Advanced Development						32
Government Contract, Base Period, Value of Award for Delivery and Support Activities, Supportive Procurement Activities						0.6
Proceeds from Delivery of Courses						$ 11.1
Number of Courses Delivered						35,700
Proceeds from Other Base Period Activities						$ 9.7
Government Contract, Value of Unexercised Options, Supportive Procurement Activities						5.6
The 19C BARDA Contract [Member] | Transferred over Time [Member]
Contract with Customer, Liability, Revenue Recognized						7.5	$ 7.4
The 19C BARDA Contract [Member] | Transferred at Point in Time [Member]
Contract with Customer, Liability, Revenue Recognized						$ 112.6	11.1
The 19C BARDA Contract [Member] | IV TPOXX [Member]
Government Contract, Base Period, Number of Courses Manufactured						20,000
Government Contract, Value, Payments Currently Specified as Unexercised Options, Delivery of Courses						$ 337.7
Government Contract, Value, Payments Related to Exercised Options, Funding of Post-Marketing Activities						$ 3.6
Government Contract, Unexercised Options, Number of Deliveries						1,089,000
Number of Manufacturing Steps						2
The 19C BARDA Contract [Member] | IV BDS [Member]
Government Contract, Base Period, Value of Award for Delivery and Support Activities, Manufacture of Courses						$ 3.2
Proceeds from the Manufacture of Courses						3.2
Contract with Customer, Liability, Total						3.2
Government Contract, Value, Payments Currently Specified as Unexercised Options, Manufacture of Courses						$ 30.7
Government Contract, Number of Options for Manufacture of Product						3
Government Contract, Courses Manufactured Upon Exercise of Options						64,000
The 19C BARDA Contract [Member] | Oral TPOXX [Member]
Number of Courses to Be Delivered						363,070
Proceeds from Delivery of Courses						$ 101.3
Number of Courses Delivered						363,000
Government Contract, Value, Payments Related to Exercised Options, Procurement of Raw Materials						$ 11.2
Government Contract, Value, Payments Currently Specified as Unexercised Options, Delivery of Courses						101.3
Government Contract, Value, Payments Related to Exercised Options, Funding of Post-Marketing Activities						14.6
Proceeds for the Procurement of Raw Materials						11.2
Proceeds for the Funding of Post-marketing Activities						5.4
The 19C BARDA Contract [Member] | IV FDP [Member]
Government Contract, Value, Payments Currently Specified as Unexercised Options, Delivery of Courses						$ 76.8
Government Contract, Value, Unexercised Options, Manufacture of Courses						192,000
Government Contract, Value, Payments Currently Specified as Unexercised Options, Manufacture of Courses						$ 76.8
Government Contract, Number of Options for Manufacture of Product						3
Government Contract, Courses Manufactured Upon Exercise of Options						64,000
The 2011 BARDA Contract [Member]
Number of Courses to Be Delivered															1,700,000
Government Contract, Value of Award						$ 508.4
Base Period of Performance (Year)		84 months
Government Contract, Value, Payments Remaining Related to Exercised Options		$ 72.7
Number of Additional Courses to be Delivered at No Additional Cost															300,000
Proceeds from the Manufacture and Delivery of Courses						$ 459.8
Number of Courses to be Manufactured						1,700,000
Proceeds from Reimbursements in Connection with Development and Supportive Activities						$ 45.6
Amount Eligible to be Received for Reimbursements of Development and Supportive Activities						3
Proceeds from Government Contract Options, Exercised			$ 50
Government Contract, Increase (Decrease) in Value of Award, FDA Approval		50
Government Contract, Value, Payments Related to Exercised Options, Development and Supportive Activities		58.3
Government Contract, Value, Payments Related to Exercised Options, Production-related Activities		$ 14.4
Cash Consideration Received								$ 375.6
Revenue, Government Contract					$ 90.9
Reduced Holdback Amount					$ 40.9
Contract Value Option FDA Approval						50
Deferred Costs, Noncurrent, Total														$ 96.5
The 2011 BARDA Contract [Member] | Transferred over Time [Member]
Contract with Customer, Liability, Revenue Recognized						0.2	0.3
The 2011 BARDA Contract [Member] | Transferred at Point in Time [Member]
Contract with Customer, Liability, Revenue Recognized						0.4	0.1
Meridian Contract [Member] | Oral TPOXX [Member] | Subsequent Event [Member]
Government Contract Receivable									$ 33
Government Contract Receivable, Remainder of Fiscal Year									3.4
Government Contract Receivable, Year One									$ 17
Canadian Contract [Member] | Meridian Medical Technologies [Member]
Government Contract Receivable	$ 14									$ 2.3
Government Contract, Term (Year)	4 years
Canadian Contract [Member] | Transferred at Point in Time [Member]
Contract with Customer, Liability, Revenue Recognized						2.3
The IV Formulation R & D Contract with BARDA [Member]
Government Contract, Future Aggregate Research and Development Funding						2.1
The IV Formulation R & D Contract with BARDA [Member] | Transferred over Time [Member]
Contract with Customer, Liability, Revenue Recognized						1.4	7.5
Contract with Customer, Asset, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price				$ 3.3			3.3
The PEP Label Expansion R & D Contract with the Department of Defense [Member]
Grants Receivable											$ 26	$ 19.5
Government Contract, Initial Award						22.4					$ 23	$ 12.4
The PEP Label Expansion R & D Contract with the Department of Defense [Member] | Transferred over Time [Member]
Contract with Customer, Liability, Revenue Recognized						$ 0.3	$ 0.3

Note 4 - Sale of Priority Rev_2

Note 4 - Sale of Priority Review Voucher (Details Textual) $ in Millions	Oct. 31, 2018USD ($)
Proceeds from Sale of Priority Review Voucher	$ 80

Note 5 - Inventory - Inventory

Note 5 - Inventory - Inventory (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Raw materials	$ 2,628,153	$ 0
Work in-process	15,415,425	8,693,457
Finished goods	2,221,941	959,398
Inventory	$ 20,265,519	$ 9,652,855

Note 6 - Property, Plant and _3

Note 6 - Property, Plant and Equipment (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Depreciation, Depletion and Amortization, Total	$ 529,814	$ 526,997	$ 69,630

Note 6 - Property, Plant and _4

Note 6 - Property, Plant and Equipment - Property, Plant and Equipment (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Property, plant and equipment, gross	$ 6,274,944	$ 6,344,616
Operating lease right-of-use asset	2,944,932	2,944,932
Less-accumulated depreciation	(4,170,954)	(3,726,313)
Property, plant and equipment, net	2,103,990	2,618,303
Leasehold Improvements [Member]
Property, plant and equipment, gross	2,420,028	2,420,028
Computer Equipment [Member]
Property, plant and equipment, gross	532,125	601,797
Furniture and Fixtures [Member]
Property, plant and equipment, gross	$ 377,859	$ 377,859

Note 7 - Accrued Expenses - Acc

Note 7 - Accrued Expenses - Accrued Expenses and Other Current Liabilities (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Deferred revenue	$ 3,280,947	$ 2,298,341
Compensation	2,933,738	2,966,139
Other	486,158	643,570
Vacation	405,176	256,402
Research and development vendor costs	327,606	707,685
Professional fees	251,824	288,707
Inventory	150,349	71,541
Interest payable	0	977,724
Income tax payable	919,555	7,093
Accrued expenses and other current liabilities	9,205,293	8,636,911
Accrued Expenses and Other Current Liabilities [Member]
Lease liability, current portion	$ 449,940	$ 419,709

Note 8 - Debt (Details Textual)

Note 8 - Debt (Details Textual) - USD ($)	Mar. 13, 2020	Nov. 16, 2016	Sep. 30, 2016	Sep. 02, 2016	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Repayments of Long-term Debt, Principal						$ 85,913,459	$ 0	$ 0
Gain (Loss) on Extinguishment of Debt, Total						(4,981,461)	0	$ 0
Warrants and Rights Outstanding						$ 6,639,211	$ 6,116,882
Warrant Issued Alongside Entry Into the Loan Agreement [Member]
Warrants and Rights Outstanding				$ 5,800,000
Loan Agreement [Member] | Term Loan [Member] | OCM Strategic Credit SIGTEC Holdings, LLC [Member]
Repayments of Long-term Debt Including Interest	$ 87,200,000
Repayments of Long-term Debt, Principal	80,000,000
Repayments of Long-term Debt, Repayment Fee	4,000,000
Interest Paid, Including Capitalized Interest, Operating and Investing Activities, Total	1,200,000
Repayments of Long-term Debt, Prepayment Premium	$ 1,900,000
Gain (Loss) on Extinguishment of Debt, Total					$ (5,000,000)
Proceeds from Issuance of Debt		$ 80,000,000
Proceeds from Issuance of Debt, Placed in Escrow			$ 80,000,000
Debt Instrument, Term (Year)				4 years
Debt Instrument, Repayment Fee				$ 4,000,000
Debt Issuance Costs, Gross				$ 8,200,000
Loan Agreement [Member] | Term Loan [Member] | OCM Strategic Credit SIGTEC Holdings, LLC [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate				11.50%
Loan Agreement [Member] | Term Loan [Member] | OCM Strategic Credit SIGTEC Holdings, LLC [Member] | US Treasury (UST) Interest Rate [Member]
Debt Instrument, Basis Spread on Variable Rate				0.50%

Note 9 - Per Share Data (Detail

Note 9 - Per Share Data (Details Textual)	12 Months Ended
	Dec. 31, 2020shares
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	1,124,585

Note 9 - Per Share Data - Recon

Note 9 - Per Share Data - Reconciliation of the Basic and Diluted Loss Per Share (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Net income (loss)	$ 56,342,010	$ (7,241,147)	$ 421,807,828
Less: Change in fair value of warrants	0	5,091,256	(6,922,624)
Net income (loss), adjusted for change in fair value of warrants for diluted earnings per share	$ 56,342,010	$ (12,332,403)	$ 428,730,452
Weighted average shares outstanding: basic (in shares)	79,259,000	81,031,254	79,923,295
Effect of potential common shares (in shares)	178,306	1,143,769	2,785,177
Weighted average shares outstanding: diluted (in shares)	79,437,306	82,175,023	82,708,472
Earnings (loss) per share: basic (in dollars per share)	$ 0.71	$ (0.09)	$ 5.28
Earnings (loss) per share: diluted (in dollars per share)	$ 0.71	$ (0.15)	$ 5.18

Note 9 - Per Share Data - Antid

Note 9 - Per Share Data - Antidilutive Securities Excluded from Computation (Details)	12 Months Ended
	Dec. 31, 2019shares
Share-based Payment Arrangement, Option [Member]
Antidilutive securities (in shares)	340,284
Stock Appreciation Rights (SARs) [Member]
Antidilutive securities (in shares)	1,666
Restricted Stock Units (RSUs) [Member]
Antidilutive securities (in shares)	525,741

Note 10 - Financial Instrumen_2

Note 10 - Financial Instruments (Details Textual) $ / shares in Units, shares in Millions	12 Months Ended
	Dec. 31, 2020USD ($)shares	Dec. 31, 2019USD ($)	Sep. 02, 2016USD ($)$ / sharesshares
Warrants and Rights Outstanding | $	$ 6,639,211	$ 6,116,882
The 2016 Warrant [Member]
Class of Warrant or Right Outstanding, Common Stock Value Used to Determine Number of Shares Called | $			$ 4,000,000
Class of Warrant or Right Outstanding, Common Stock Price Per Share Used to Determine Number of Shares Called (in dollars per share) | $ / shares			$ 2.29
Class of Warrant or Right, Subscription Price of Warrants or Rights (in dollars per share) | $ / shares			1.50
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 1.50
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares	1		2.7
Class of Warrant or Right, Exercised During Period (in shares) | shares	0.5
Warrants and Rights Outstanding, Term (Year)	10 years
Warrants and Rights Outstanding | $	$ 6,600,000	$ 6,100,000	$ 5,800,000
The 2016 Warrant [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0.0046	0.0181
The 2016 Warrant [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0	0
The 2016 Warrant [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input	5.7	6.7
The 2016 Warrant [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input	0.80	0.70

Note 11 - Stockholders' Equity

Note 11 - Stockholders' Equity (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2020	Mar. 05, 2020	Dec. 31, 2019
Capital Units, Authorized (in shares)	620,000,000
Common Stock, Shares Authorized (in shares)	600,000,000		600,000,000
Preferred Stock, Shares Authorized (in shares)	20,000,000
Preferred Stock, Shares Outstanding, Ending Balance (in shares)	0		0
Stock Repurchase Program, Authorized Amount		$ 50,000,000
Stock Repurchased During Period, Shares (in shares)	4,600,000
Stock Repurchased During Period, Value	$ 28,502,946
Preferred Stock, Shares Issued, Total (in shares)	0		0

Note 12 - Stock Compensation _3

Note 12 - Stock Compensation Plans (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	May 23, 2017	Apr. 25, 2012	May 17, 2011
Share-based Payment Arrangement, Expense	$ 1,400,000	$ 2,100,000	$ 2,300,000
Stock Options [Member]
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	383,000	$ 120,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares (in shares)		0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value	87,000	$ 76,000	$ 2,900,000
Restricted Stock Units (RSUs) [Member]
Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount	$ 500,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)	6 months
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)	$ 5.95	$ 5.84	$ 6.53
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value	$ 1,000,000	$ 1,600,000	$ 2,900,000
Restricted Stock Units (RSUs) [Member] | Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)	1 year
The 2010 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)				8,500,000	4,500,000	2,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)	10 years

Note 12 - Stock Compensation _4

Note 12 - Stock Compensation Plans - Stock Options Activity (Details) - Stock Options [Member] $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2020USD ($)$ / sharesshares
Outstanding (in shares) | shares	281,000
Outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 9.68
Granted (in shares) | shares	75,000
Granted, weighted average exercise price (in dollars per share) | $ / shares	$ 6.47
Exercised (in shares) | shares	(25,000)
Exercised, weighted average exercise price (in dollars per share) | $ / shares	$ 3.89
Canceled/Expired (in shares) | shares	(78,000)
Canceled/Expired, weighted average exercise price (in dollars per share) | $ / shares	$ 8.13
Outstanding (in shares) | shares	253,000
Outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 9.78
Outstanding, weighted average remaining life (Year)	3 years 5 months 19 days
Outstanding, aggregate intrinsic value | $	$ 170
Vested (in shares) | shares	253,000
Vested, weighted average exercise price (in dollars per share) | $ / shares	$ 9.78
Vested, weighted average remaining life (Year)	3 years 5 months 19 days
Vested, aggregate intrinsic value | $	$ 170
Exercisable (in shares) | shares	253,000
Exercisable, weighted average exercise price (in dollars per share) | $ / shares	$ 9.78
Exercisable, weighted average remaining life (Year)	3 years 5 months 19 days
Exercisable, aggregate intrinsic value | $	$ 170

Note 12 - Stock Compensation _5

Note 12 - Stock Compensation Plans - Restricted Stock and Restricted Stock Units (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Outstanding (in shares)	240,292
Outstanding, weighted average grant date fair value (in dollars per share)	$ 5.83
Granted (in shares)	135,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)	$ 5.95	$ 5.84	$ 6.53
Vested and released (in shares)	(177,876)
Vested and released, weighted average grant date fair value (in dollars per share)	$ 5.84
Canceled/Expired (in shares)	(30,000)
Canceled/Expired, weighted average grant date fair value (in dollars per share)	$ 6.20
Outstanding (in shares)	167,416	240,292
Outstanding, weighted average grant date fair value (in dollars per share)	$ 5.86	$ 5.83

Note 13 - Income Taxes (Details

Note 13 - Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	$ (24,873)
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%	21.00%	21.00%
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	$ 5,600,000
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total	$ 65,000	$ 38,000
Domestic Tax Authority [Member]
Open Tax Year	2017 2018 2019 2020
State and Local Jurisdiction [Member]
Open Tax Year	2016 2017 2018 2019 2020

Note 13 - Income Taxes - Compon

Note 13 - Income Taxes - Components of Income Tax Expense Benefit (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Federal	$ 5,111,667	$ (663,114)	$ (1,326,022)
State and local	447,965	143,455	459,172
Total current provision (benefit)	5,559,632	(519,659)	(866,850)
Federal	11,375,962	(2,092,585)	(9,256,661)
State and local	230,987	(325,032)	(44,761)
Total deferred provision (benefit)	11,606,949	(2,417,617)	(9,301,422)
Total provision (benefit)	$ 17,166,581	$ (2,937,276)	$ (10,168,272)

Note 13 - Income Taxes - Deferr

Note 13 - Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Net operating losses	$ 1,293,842	$ 9,353,603
Amortization of intangible assets	80,930	113,910
Share-based compensation	398,165	451,818
Deferred revenue	709,480	719,304
Interest expense carryforward	0	2,617,951
Lease liability	520,830	678,993
Alternative minimum tax credits	0	663,114
Other	1,141,705	1,338,046
Deferred income tax assets	4,144,952	15,936,739
Less: valuation allowance	(1,022,135)	(1,047,008)
Deferred income tax assets, net of valuation allowance	3,122,817	14,889,731
Amortization of goodwill	(199,172)	(201,930)
Property, plant and equipment	(81,065)	(175,581)
Other	(298,527)	(361,218)
Deferred income tax asset, net	$ 2,544,053	$ 14,151,002

Note 13 - Income Taxes - Effect

Note 13 - Income Taxes - Effective Tax Rate Reconciliation (Details)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%	21.00%	21.00%
State and local taxes	0.70%	1.30%	0.80%
Change in fair value of common stock warrant	1.00%	10.50%	0.40%
Section 162(m) limitation	0.50%	(6.00%)	0.30%
Other	0.20%	2.10%	(0.30%)
Valuation allowance on deferred tax assets	0.00%	0.00%	(24.70%)
Effective tax rate	23.40%	28.90%	(2.50%)

Note 13 - Income Taxes - Unreco

Note 13 - Income Taxes - Unrecognized Tax Benefits Roll Forward (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Balance at beginning of year	$ 5,649,188	$ 5,738,964	$ 0
Additions	0	0	5,738,964
Reductions	(57,601)	(89,776)	0
Settlements	0	0	0
Lapses in applicable statutes of limitation	0	0	0
Balance at the end of the year	$ 5,591,587	$ 5,649,188	$ 5,738,964

Note 14 - Commitments and Con_3

Note 14 - Commitments and Contingencies (Details Textual) $ in Millions	12 Months Ended
	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	May 26, 2017ft²
Operating Lease, Cost	$ 0.7	$ 0.6
Operating Lease, Payments	$ 0.6	$ 0.6
Operating Lease, Weighted Average Remaining Lease Term (Year)	5 years 8 months 12 days
Operating Lease, Weighted Average Discount Rate, Percent	4.53%
Purchase Commitment, Remaining Minimum Amount Committed	$ 12.5
Other Noncurrent Liabilities [Member]
Operating Lease, Liability, Noncurrent	$ 1.9
The New HQ Lease [Member] | MacAndrews and Forbes Incorporated [Member]
Lessee, Operating Lease, Term of Contract (Year)			10 years
Area of Real Estate Property (Square Foot) | ft²			3,200

Note 14 - Commitments and Con_4

Note 14 - Commitments and Contingencies - Maturity of Lease Liabilities (Details)	Dec. 31, 2020USD ($)
2021	$ 550,904
2022	368,467
2023	402,078
2024	404,258
2025	406,994
Thereafter	575,887
Total undiscounted cash flows under operating leases	2,708,588
Less: Imputed interest	(359,467)
Other Liabilities [Member]
Present value of lease liabilities	$ 2,349,121

Note 15 - Related Party Trans_2

Note 15 - Related Party Transactions (Details Textual)	Jul. 31, 2017USD ($)	May 26, 2017USD ($)ft²	Jan. 09, 2013USD ($)ft²	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Oct. 13, 2018USD ($)
Outside Counsel [Member]
Legal Fees				$ 478,000	$ 468,000	$ 450,000
Accounts Payable, Related Parties				78,000
Dr. Eric A. Rose [Member] | Consulting Agreement [Member]
Accounts Payable, Related Parties				7,000
Related Party Transaction, Annual Amount							$ 200,000
Related Party Transaction, Expenses from Transactions with Related Party				$ 157,000
MacAndrews and Forbes Incorporated [Member] | The New HQ Lease [Member]
Area of Real Estate Property (Square Foot) | ft²		3,200
Monthly Rent During Initial Period		$ 25,333
Monthly Rent, Initial Period (Month)		63 months
Monthly Rent After Initial Period		$ 29,333
Monthly Facility Fee, Second Year		$ 3,333
Monthly Facility Fee, Yearly Rate Increase After Second Year		5.00%
Monthly Facility Fee, Final Year		$ 4,925
MacAndrews and Forbes Incorporated [Member] | The Old HQ Sublease [Member]
Area of Real Estate Property (Square Foot) | ft²			6,676
Monthly Rent During Initial Period			$ 60,000
Monthly Rent After Initial Period			$ 63,400
MacAndrews and Forbes Incorporated [Member] | The Replacement M&F Sublease [Member]
Rent Concession Period (Month)	2 months
Monthly Rent, First Twelve Months	$ 36,996
Monthly Rent, Year Two	37,831
Monthly Rent, Thereafter	$ 38,665